pX330-TP53-1 Citations (1)
Originally described in: MDM2 and MDM4 are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.Howard TP, Arnoff TE, Song MR, Giacomelli AO, Wang X, Hong AL, Dharia NV, Wang S, Vazquez F, Pham MT, Morgan AM, Wachter F, Bird GH, Kugener G, Oberlick EM, Rees MG, Tiv HL, Hwang JH, Walsh KH, Cook A, Krill-Burger JM, Tsherniak A, Gokhale PC, Park PJ, Stegmaier K, Walensky LD, Hahn WC, Roberts CWM Cancer Res. 2019 Feb 12. pii: 0008-5472.CAN-18-3066. doi: 10.1158/0008-5472.CAN-18-3066. PubMed Journal
Articles Citing pX330-TP53-1
| Articles |
|---|
| Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. Cordova RA, Sommers NR, Law AS, Klunk AJ, Brady KE, Goodrich DW, Anthony TG, Brault JJ, Pili R, Wek RC, Staschke KA. Sci Signal. 2024 Nov 26;17(864):eadp1375. doi: 10.1126/scisignal.adp1375. Epub 2024 Nov 26. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.